BRCA1 and breast carcinoma: Together, they are referred as BRCAness.8 While targeted therapies are available for other subtypes of breast cancer, TNBCs currently lack targeted therapies (except BRCA1 mutated ones) and their treatment relies heavily on broad cytotoxic chemotherapeutic agents.9